CAP 17 Setembre
- Address
- lock Available on a paid plan
CAP 17 Setembre - Cardiovascular Disease Prevention Research Center
CAP 17 Setembre is a specialized clinical research facility dedicated to advancing cardiovascular disease prevention and treatment. The center focuses on investigating novel therapeutic interventions for patients with atherosclerotic cardiovascular disease (ASCVD) and those at high risk for cardiovascular events, with particular expertise in lipid-lowering therapies and their impact on major adverse cardiovascular outcomes.
- Primary and secondary prevention of atherosclerotic cardiovascular disease
- Evaluation of LDL-cholesterol lowering therapies using inclisiran
- Prevention of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, and stroke
The research center conducts large-scale, randomized, double-blind, placebo-controlled trials examining the effectiveness of innovative medications in reducing cardiovascular mortality, heart attacks, and strokes. Their studies encompass both high-risk primary prevention populations and patients with established vascular disease, contributing essential evidence for improving cardiovascular outcomes and reducing the burden of atherosclerotic disease in diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CAP 17 Setembre
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| European Clinical Research Alliance on Infectious Diseases – primary care adaptive platform trial for pandemics and epidemics (ECRAID-Prime) | Universitair Medisch Centrum Utrecht | Phase IV | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.